464 results about "Pneumonitis" patented technology

The invention provides a metal polyphenol nanoparticle, a preparation method thereof and an application of the metal polyphenol nanoparticle in preparation of a medicine for treating acute lung injury, the metal polyphenol nanoparticle is formed by self-assembly of metal ions and polyphenol, the metal ions are selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >, and the polyphenol is selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >. The polyphenol is selected from epigallocatechin gallate (EGCG), caffeic acid (CA), chlorogenic acid (CGA), gallic acid (GA) and luteolin (LUT). The metal polyphenol nanoparticles are used for preparing a medicine for treating acute lung injury induced by sepsis, pneumonia, serious trauma or inhalation injury, and the medicine further comprises a pharmaceutically acceptable carrier. The metal polyphenol nanoparticles provided by the invention are simple in preparation process and high in biological safety, polyphenol and metal ions synergistically enhance the anti-inflammatory and antioxidant activity, and the metal polyphenol nanoparticles are superior to the single use of polyphenol or metal ions.

The invention relates to the field of biological medicine, and discloses a method and system for analyzing cough sound by using disease characteristics to diagnose respiratory diseases, and the method comprises the steps: deploying a six-microphone annular array to achieve the precise positioning and triggering of a sound source; self-adaptive spectral subtraction and Wiener filtering cascade are adopted to enhance the audio; segmenting a cough segment based on energy envelope; fusing the Mel-cepstrum, the linear prediction residual error, the harmonic energy ratio and the transient zero-crossing rate to construct a pathological feature matrix; extracting local, medium-range and global time sequence features through a three-branch parallel convolutional network; inputting a disease specific classifier to discriminate asthma, pneumonia and laryngitis respectively, and applying a feature decoupling regular term to improve interpretability. The system correspondingly realizes the modularized processing flow. According to the method, the cough sound collection quality and the disease subtype recognition accuracy in a complex environment are improved, meanwhile, the thermodynamic diagram is output to assist clinical decision making, and the diagnosis credibility and practicability are enhanced.

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention provides application of a probiotic composition in preparation of a medicine for preventing and / or treating pneumonia, and belongs to the technical field of biological medicine. The probiotic composition comprises sophora flower bud powder, a broccoli seed aqueous extract, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Research finds that the probiotic composition can significantly relieve pulmonary edema caused by pneumonia and also can significantly reduce the level of inflammatory factors in pneumonia, so that the probiotic composition has the effect of preventing and / or treating pneumonia, and more choices are provided for clinical drugs for preventing and / or treating pneumonia.

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention discloses an application of a THBS1 inhibitor in preparation of a medicine for preventing or treating lung tissue inflammation induced by novel coronavirus, and provides a related medicine, application and a method, the THBS1 gene inhibitor or a TSP-1 protein inhibitor is used for treating the lung tissue inflammation infected by SARS-CoV-2, the effect is remarkable, and the medicine can be used for preparing medicines for preventing or treating the lung tissue inflammation induced by the novel coronavirus. The SARS-CoV-2 gene is a novel target for treating severe pneumonia caused by SARS-CoV-2 infection.

The embodiment of the invention provides a traditional Chinese medicine preparation for improving lung qi and yin deficiency constitution and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials: 1-3 parts of American ginseng, 2-15 parts of Chinese yam, 1.5-9 parts of codonopsis pilosula, 1-6 parts of dendrobium officinale, 1.5-9 parts of rhizoma polygonati, 0.5-2 parts of schisandra chinensis, 2-6 parts of lily, 1-3 parts of pericarpium citri reticulatae, 1-2 parts of liquorice, 1-5 parts of folium mori, 1-3 parts of donkey-hide gelatin, 1-3 parts of mint, 1-6 parts of angelica sinensis and 2-9 parts of coix seeds. Therefore, the traditional Chinese medicine composition has the functions of tonifying qi and yin, clearing heat and moistening lung, replenishing blood and promoting salivation, and relieving cough and reducing sputum, and can be widely applied to chronic cough, various pneumonia, pulmonary tuberculosis, chronic obstructive pulmonary disease, lung malignant tumor, asthma remission period of asthma, respiratory failure and other syndrome-differentiated lung qi and yin deficiency patients.

The invention belongs to the technical field of radiooncology, artificial intelligence and medical image fusion, and particularly relates to a model construction method and system for predicting the radiation pneumonitis risk of a patient receiving immune combined radiotherapy. According to the method, for a non-small cell lung cancer patient receiving immune checkpoint inhibitor (ICIs) combined radiotherapy, clinical information and radiotherapy dose parameters of the patient are collected, a positioning CT image and dynamic immune factor data are simulated, multi-source features including radiomics features, an immune change curve and dose volume indexes are extracted, and a multi-modal fusion prediction model is constructed. The system integrates automatic data input, feature extraction, model training and risk output modules, can output individual radiation pneumonitis risk scores, provides risk grading and dose intervention suggestions, and has high prediction accuracy and clinical interpretability. The method can be widely applied to individualized risk management and precise treatment of non-small cell lung cancer immune combined radiotherapy patients.

The invention discloses lactobacillus paracasei for improving urticaria and Alzheimer's disease and a product, and relates to the technical field of microorganisms. The lactobacillus paracasei NHNK-1701 disclosed by the invention is preserved in the China Center for Type Culture Collection on April 14, 2025, and the preservation number of the lactobacillus paracasei NHNK-1701 is CCTCC (China Center for Type Culture Collection) NO: M 2025765. The NHNK-1701 has the effects of inhibiting the growth of the klebsiella pneumoniae and / or generating alcohol, agglutinating the klebsiella pneumoniae, tolerating 10% of alcohol, reducing alcohol-induced injury of skin cutin barrier and inflammation, reducing alcohol-induced injury of brain microvascular barrier and inflammation, improving the klebsiella pneumoniae-induced injury survival rate of brain microvascular endothelial cells and improving the activity of the brain microvascular endothelial cells. Klebsiella pneumonia induced damage to brain microvascular barriers and inflammation is reduced, and Klebsiella pneumonia induced damage to intestinal barriers and inflammation is reduced.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The present invention relates to a composition for treatment of coronavirus disease 2019 (COVID-19) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, an early full recovery effect has been confirmed through the efficacy of treating clinical symptoms caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, alleviating inflammation, and inhibiting inflammatory cytokines using a pharmaceutically acceptable salt of taurodeoxycholic acid, and thus the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in a composition for prevention or treatment of lower respiratory tract infectious diseases, including coronavirus disease 2019.

The invention discloses a lung function evaluation method for a patient in a pneumonia rehabilitation period, and relates to the technical field of rehabilitation management. Extracting a lung function feature set based on the image data; analyzing based on multi-dimensional parameter association, and establishing a dynamic mapping relationship between the lung function feature set and associated physiological parameters; identifying abnormal associated parameters through a dynamic mapping relation between the lung function feature set and the associated physiological parameters, and when the deviation between the image feature recovery degree and the corresponding physiological parameter recovery degree exceeds a preset threshold value, judging that functional abnormal parameters exist; and matching a potential complication database based on the abnormal parameter type, analyzing the relevance between the abnormal parameter and a preset disease feature model, and outputting secondary disease risk early warning. The method has the advantages that through cross-modal fusion of the lung image features and the dynamic physiological parameters, the early recognition precision of the pneumonia convalescence complication is remarkably improved.

The invention provides a pneumonia medical data analysis and processing method, system and device and a storage medium, and belongs to the field of medical image processing. Multi-scale features of the lung CT image are extracted layer by layer through convolution, global pooling operation down-sampling is carried out based on the multi-scale features, and saliency features of lung lobe and lesion areas are captured from local details to global semantics; performing convolution and multi-scale pooling on the saliency features to generate a feature map fusing global and local information; and recovering the feature map through layer-by-layer up-sampling to obtain a segmentation result of the lung lobe and the focus. Quantitative indicators are calculated based on regions and pixels of the segmentation results of the lung lobes and lesions. And performing model processing based on the quantitative index, the segmentation result of the lung lobe and the focus and clinical data of the lung lobe and the patient to obtain pneumonia focus characteristic data. And a doctor can conveniently make an objective and reasonable treatment scheme according to a result of lesion segmentation and feature data calculation based on the pneumonia lesion feature data.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The present invention provides a Lactiplantibacillus plantarum strain capable of resisting Streptococcus pneumoniae infection in the respiratory tract, with a deposit number of CCTCC NO: M2022359. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has a strong adhesion effect on nasal epithelial cells and can colonize in the nasal cavity; and can significantly inhibit the adhesion effect of Streptococcus pneumoniae, the main pathogenic microorganism of sinusitis, on nasal epithelial cells; it also has an inhibitory effect on the growth of most other pathogenic microorganisms of sinusitis, including β-hemolytic streptococcus, Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, etc. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has no toxic effect on the body and has good safety. It can be added to drugs for preventing respiratory diseases or improving respiratory symptoms caused by bacterial infections, and has broad application prospects.

The invention discloses a construction and evaluation method of a PM2.5 induced chronic obstructive pulmonary disease acute exacerbation mouse model, and relates to the technical field of disease animal models. The invention aims to evaluate whether PM2.5 can induce acute exacerbation of COPD through a mouse model, a COPD model is established by adopting combined treatment of smoking and lipopolysaccharide (LPS), and an infectious AECOPD model is established by using common klebsiella pneumoniae (KP) nasal drop on the basis. Meanwhile, PM2.5 processing is added on the basis of the COPD model, and the effect of PM2.5 on acute exacerbation of COPD is evaluated. Through comparison with a classical model (an infectious AECOPD model), the potential effect of PM2.5 in induction of acute exacerbation of COPD is evaluated, and an important reference is provided for future research on an AECOPD animal model induced by air pollution.

The utility model provides an atomizing mask. The atomization cover comprises a cover body, a medicine inlet pipe and a breathing hole, the cover body is worn on the face of the human body, the medicine inlet pipe is connected to the cover body, and the breathing hole is formed in the cover body. The shielding assembly comprises a shielding plate and a plurality of mounting parts, the mounting parts are detachably mounted on the medicine inlet pipe, and the shielding plate is mounted on the mounting parts, shields the mouth of the human body and is configured to abut against the mouth of the human body under the action of the mounting parts. The utility model further provides an atomizer which comprises an atomizing mask and an atomizer body, and the atomizer body is detachably installed at the end, away from the shielding plate, of the medicine inlet pipe. According to the atomization mask, when rhinitis, nasosinusitis, bronchitis, pneumonia and other diseases are treated, liquid medicine is prevented from flowing back into the oral cavity of a user, it is guaranteed that the atomized liquid medicine is sucked into the airway of a patient as much as possible, the treatment effect of the device is improved, and the treatment effect is improved. The liquid medicine can be prevented from entering the oral cavity, so that the use comfort of a user is reduced, and bacterial infection is avoided.

The invention discloses a medical image segmentation method based on a Kolmogorov-Arnold network, and the method comprises the steps: firstly obtaining a medical image, then constructing an IKANet model, and carrying out the segmentation of the medical image after training, testing and verification. Wherein the IKANet model adopts an encoder-decoder structure and integrates three core components, namely a DKC module, a multi-scale attention module and an interpretability analysis module, and the DKC module realizes adaptive nonlinear transformation and feature decoupling through a Kolmogorov-Arnold network; the multi-scale attention module enhances space-channel feature fusion through multi-scale convolution and a channel attention mechanism; and the interpretability analysis module generates a multi-scale class activation mapping thermodynamic diagram and provides visual interpretation. The technical problems that an existing medical image segmentation method is limited in generalization ability and insufficient in interpretability are solved, and the method can be widely applied to data sets of colon polyp, pneumonia, pneumothorax and the like.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The invention belongs to the technical field of molecular biology, and particularly relates to a construction method and application of a streptococcus pneumoniae pneumonia animal model. The invention provides a construction method of a streptococcus pneumoniae infected rat pneumonia and kidney injury model. The method comprises the following steps: S1, applying a streptococcus pneumoniae liquid into the respiratory tract of a rat by adopting an atomization bacterium feeding mode; and S2, verifying whether the rat treated in the step S1 is infected with pneumonia or not and whether kidney injury exists or not. According to the method, whether pneumonia is infected or not is judged by detecting inflammatory factors in alveolar lavage and lung HE staining, and whether kidney injury exists or not is judged by detecting the urine protein / creatinine ratio in a rat urine sample and detecting kidney HE staining. The construction method provided by the invention is convenient to operate, accurate in model construction and high in survival rate.

This invention provides a novel nebulization suspension comprising amoxicillin and clavulanate for the effective treatment of pneumonia. The formulation is specifically designed for pulmonary delivery, offering several advantages over traditional oral antibiotics. Key features include mucoadhesive properties that enhance drug retention 5 in the lungs, sustained release characteristics for prolonged therapeutic action, and potential biofilm disruption to combat antibiotic resistance. This localized delivery approach aims to minimize systemic side effects, improve treatment efficacy, and address the growing challenge of antibiotic resistance in pneumonia.

The invention discloses application of hesperidin in preparation of a medicine for preventing and / or treating porcine contagious pleuropneumonia, and belongs to the field of biological medicine. The concentration of the hesperidin is 6.25-25 [mu] g / mL, and cell experiments prove that the hesperidin can inhibit cell inflammatory response and reduce expression of inflammatory factors, and can effectively relieve the actinobacillus pleuropneumoniae induced endovascular dermatitis injury by inhibiting activation of CD14 / TLR4-NF [kappa] B P65. Animal experiments prove that the hesperidin can relieve pathological changes and injuries of various tissues and organs after actinobacillus pleuropneumoniae infection, improve weight loss caused by actinobacillus pleuropneumoniae infection, relieve inflammatory response and metabolic dysfunction caused by actinobacillus pleuropneumoniae, and improve the body weight loss caused by actinobacillus pleuropneumoniae. The composition plays a role in protecting organisms infected by actinobacillus pleuropneumoniae. The invention provides a new scientific basis for controlling porcine contagious pleuropneumonia by using natural medicines.

In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.

The invention relates to the technical field of medical image analysis, in particular to a radiation pneumonitis prediction system and method after chest tumor radiotherapy, and the system comprises a structure hot area extraction module, a density breakpoint recognition module, a disturbance trajectory analysis module, a path clustering matching module and a risk trend output module. According to the method, through continuous arrangement of voxel gray scale ratios on a time axis and coincidence extraction of the voxel gray scale ratios and a dose region, precise positioning of a functional latent active region and sensitive identification of an evolution trend are realized, time sequence variation analysis is enhanced, and in combination with gray scale direction reversal point extraction, quantitative definition of a texture mutation region is improved; unifying ventilation and perfusion path time axes, dynamically mastering the continuity and mutability of functional disturbance of the pulmonary segment, completing behavior clustering based on trajectory consistency and inflection point alignment rate, enhancing the classification and evaluation ability of evolution trend, extracting a disturbance trend synchronization interval, and enhancing prospective identification of key early warning events. And the risk expression has higher hierarchy and timeliness.